Kidney Cancer Vaccines

Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for kidney cancer vaccine development and guarantee the finest results for our customers all over the world.

Kidney Cancer

Kidney cancer, also known as renal cancer, is a cancer which starts in the kidney cells. The two most common types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) (also known as urothelial cell carcinoma), depending on the type of cell from which the cancer develops. RCC accounts for about 80% of primary renal cancer while TCC accounts for the majority of the rest. Different types of kidney cancer develop in different ways, which means that these diseases have different long-term outcomes and require different ways of staging and treatment.

The most common signs and symptoms of kidney cancer are hematuria and abdominal mass. Other symptoms may include loss of appetite, weight loss, tiredness, high temperature, heavy sweating, and persistent abdominal pain. Factors that increase the risk of kidney cancer include smoking, obesity, faulty genes, family history, regular use of non-steroidal anti-inflammatory drugs such as ibuprofen and naproxen, hepatitis C infection, and kidney disease requiring dialysis. The treatment of kidney cancer depends on the type and stage of the disease. Surgery is the most common treatment because kidney cancer does not often respond to radiotherapy or chemotherapy.

Therapeutic Vaccines for Kidney Cancer

AGS-003 is an autologous dendritic cell (DC) vaccine consisting of DCs coelectroporated with the synthetic CD40L RNA and the patient’s amplified tumor RNA. When injected into patients, CD40 ligation leads to a production of IL-12, thus optimizing CD8+ T cell induction. Additionally, these RNA-containing DCs present patient-specific antigens to T cells, thereby enhancing the immune response.

IMA901 is a cancer vaccine comprised of nine HLA-A*02-restricted tumorassociated peptides (TUMAPs) and one human leukocyte antigen-antigen D-related (HLA-DR)-restricted TUMAP. Phase I/II trials with IMA901 plus immunomodulators cyclophosphamide and granulocyte-monocyte colonystimulating factor (GM-CSF) in patients with mRCC demonstrated an association between OS and responses to multiple TUMAPs. Similarly, specific populations of myeloid-derived suppressor cells (MDSCs) were prognostic for OS.

Tumor-mediated suppression of the immune system represents the major hurdle facing vaccine therapy of RCC. The key is to identify the subset of patients in whom vaccine therapy will be most beneficial. Patients in the high-risk adjuvant setting and those with minimal disease are most likely to benefit because they are least likely to mount tumor suppression of the immune system. In contrast, patients with advanced disease are likely to have significant tumor immunosuppression, and therefore, combination strategies will be needed. Once tumor-associated antigens specific for RCC are identified, and the issue of tumor immunosuppression is solved, it will be possible to take the next step forward in making vaccine therapy a viable treatment option.

Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the development of the kidney cancer vaccines. If you are interested in our services, please contact us for more details.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.